Showing results (271-280 of 315) with videos related to

Sort By:
Pageof 32
FEMS Microbiology Letters|February 2, 2006
The aflatoxin pathway regulator AflR induces gene transcription inside and outside of the aflatoxin biosynthetic clusterMichael S Price, Jiujiang Yu, William C Nierman, et al.
Medical Mycology|February 23, 2022
The current state of Clinical Mycology in Eastern and South-Eastern EuropeCândida Driemeyer, Diego R Falci, Martin Hoenigl, et al.
The Lancet. Microbe|January 31, 2022
The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countriesMartin Hoenigl, Danila Seidel, Agostinho Carvalho, et al.
Medical Mycology|June 27, 2024
Mucorales: A systematic review to inform the World Health Organization priority list of fungal pathogensC Orla Morrissey, Hannah Yejin Kim, Katherine Garnham, et al.
Mbio|October 12, 2022
Efficacy of APX2039 in a Rabbit Model of Cryptococcal MeningitisCharles D Giamberardino, Wiley A Schell, Jennifer L Tenor, et al.
The Journal of Infectious Diseases|May 23, 2018
Novel Treatment of Cryptococcal Meningitis via Neurapheresis TherapyGordon J Smilnak, Lefko T Charalambous, Drew Cutshaw, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 18, 2006
Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infectionsIssam I Raad, John R Graybill, Ana Beatriz Bustamante, et al.
Diagnostic Microbiology and Infectious Disease|March 16, 2010
Microfluidic platform versus conventional real-time polymerase chain reaction for the detection of Mycoplasma pneumoniae in respiratory specimensElizabeth Wulff-Burchfield, Wiley A Schell, Allen E Eckhardt, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 6, 2010
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of americaJohn R Perfect, William E Dismukes, Francoise Dromer, et al.
Contemporary Clinical Trials Communications|October 29, 2021
A randomized, double-blind, placebo-controlled clinical trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia (Valley Fever) in adults presenting with community-acquired pneumonia in endemic areas (FLEET-Valley Fever)Julia A Messina, Eileen K Maziarz, John Galgiani, et al.
Pageof 32